We conducted a survey of 20 infectious diseases specialists to evaluate current drug usage for the treatment of selected severe/inpatient infections and gauge physician interest in new drugs.
Drug candidates discussed: Cubicin (daptomycin), Dalvance (dalbavancin), Orbactiv (oritavancin), Zyvox (linezolid), vancomycin, metronidazole, Dificid (fidaxomicin), Xifaxan (rifaximin); beta-lactam–beta-lactamase inhibitor combination drugs.
Disease Group Covered: |
Infectious disease |

Figure: Breakdown of Surveyed Oncologists